194 related articles for article (PubMed ID: 23116626)
1. Extended adjuvant endocrine therapy in hormone dependent breast cancer: the paradigm of the NCIC-CTG MA.17/BIG 1-97 trial.
Higgins MJ; Liedke PE; Goss PE
Crit Rev Oncol Hematol; 2013 Apr; 86(1):23-32. PubMed ID: 23116626
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
Delea TE; Karnon J; Smith RE; Johnston SR; Brandman J; Sung JC; Gross PE
Am J Manag Care; 2006 Jul; 12(7):374-86. PubMed ID: 16834524
[TBL] [Abstract][Full Text] [Related]
3. Beyond tamoxifen: extended and late extended endocrine therapy in postmenopausal early breast cancer.
Dodwell D; Williamson D
Cancer Treat Rev; 2008 Apr; 34(2):137-44. PubMed ID: 18006236
[TBL] [Abstract][Full Text] [Related]
4. Extended adjuvant endocrine therapy in hormone-receptor positive breast cancer.
Strasser-Weippl K; Badovinac-Crnjevic T; Fan L; Goss PE
Breast; 2013 Aug; 22 Suppl 2():S171-5. PubMed ID: 24074782
[TBL] [Abstract][Full Text] [Related]
5. Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17.
Muss HB; Tu D; Ingle JN; Martino S; Robert NJ; Pater JL; Whelan TJ; Palmer MJ; Piccart MJ; Shepherd LE; Pritchard KI; He Z; Goss PE
J Clin Oncol; 2008 Apr; 26(12):1956-64. PubMed ID: 18332474
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone receptor-positive postmenopausal women with early-stage breast cancer.
Delea TE; Karnon J; Sofrygin O; Thomas SK; Papo NL; Barghout V
Clin Breast Cancer; 2007 Jun; 7(8):608-18. PubMed ID: 17592673
[TBL] [Abstract][Full Text] [Related]
7. Understanding the BIG results: Insights from the BIG 1-98 trial analyses.
Wardley AM
Adv Ther; 2008 Dec; 25(12):1257-75. PubMed ID: 19096768
[TBL] [Abstract][Full Text] [Related]
8. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
Coates AS; Keshaviah A; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Smith I; Chirgwin J; Nogaret JM; Pienkowski T; Wardley A; Jakobsen EH; Price KN; Goldhirsch A
J Clin Oncol; 2007 Feb; 25(5):486-92. PubMed ID: 17200148
[TBL] [Abstract][Full Text] [Related]
9. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
; Thürlimann B; Keshaviah A; Coates AS; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Rabaglio M; Smith I; Wardley A; Price KN; Goldhirsch A
N Engl J Med; 2005 Dec; 353(26):2747-57. PubMed ID: 16382061
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective.
Delea TE; El-Ouagari K; Karnon J; Sofrygin O
Breast Cancer Res Treat; 2008 Apr; 108(3):375-87. PubMed ID: 17653859
[TBL] [Abstract][Full Text] [Related]
11. Cost utility analysis of early adjuvant letrozole or anastrozole versus tamoxifen in postmenopausal women with early invasive breast cancer: the UK perspective.
Karnon J; Delea T; Barghout V
Eur J Health Econ; 2008 May; 9(2):171-83. PubMed ID: 17602251
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of letrozole versus tamoxifen as first-line hormonal therapy in treating postmenopausal women with advanced breast cancer in Japan.
Okubo I; Kondo M; Toi M; Ochiai T; Miki S
Gan To Kagaku Ryoho; 2005 Mar; 32(3):351-63. PubMed ID: 15791818
[TBL] [Abstract][Full Text] [Related]
13. Extended breast cancer treatment with an aromatase inhibitor (Letrozole) after tamoxifen: why, who and how long?
Kaufmann M; Rody A
Eur J Obstet Gynecol Reprod Biol; 2006 Jun; 126(2):146-54. PubMed ID: 16621229
[TBL] [Abstract][Full Text] [Related]
14. Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: a systematic review.
Eisen A; Trudeau M; Shelley W; Messersmith H; Pritchard KI
Cancer Treat Rev; 2008 Apr; 34(2):157-74. PubMed ID: 18164821
[TBL] [Abstract][Full Text] [Related]
15. Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.
Carpenter R
Eur J Surg Oncol; 2008 Jul; 34(7):746-55. PubMed ID: 18296017
[TBL] [Abstract][Full Text] [Related]
16. The Breast International Group 1-98 trial: big results for women with hormone-sensitive early breast cancer.
Monnier AM
Expert Rev Anticancer Ther; 2007 May; 7(5):627-34. PubMed ID: 17492927
[TBL] [Abstract][Full Text] [Related]
17. Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women.
Gradishar WJ
Oncology; 2005; 69(1):1-9. PubMed ID: 16088229
[TBL] [Abstract][Full Text] [Related]
18. Prognostic and predictive effects of diabetes, hypertension, and coronary artery disease among women on extended adjuvant letrozole: NCIC CTG MA.17.
Goodwin RA; Jamal R; Booth CM; Goss PE; Eisenhauer EA; Tu D; Shepherd LE
Eur J Cancer; 2016 May; 58():97-103. PubMed ID: 26986765
[TBL] [Abstract][Full Text] [Related]
19. The extended adjuvant NCIC CTG MA.17 trials: initial and rerandomization studies.
Pritchard KI; Goss PE; Shepherd L
Breast; 2006 Feb; 15 Suppl 1():S14-20. PubMed ID: 16500236
[TBL] [Abstract][Full Text] [Related]
20. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses.
Baum M; Buzdar A; Cuzick J; Forbes J; Houghton J; Howell A; Sahmoud T;
Cancer; 2003 Nov; 98(9):1802-10. PubMed ID: 14584060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
